

**List of publications (updated October 1<sup>st</sup> 2013)**

**Original research articles**

128. Nencioni A, da Silva RF, Fraga-Silva RA, Steffens S, Fabre M, Bauer I, Caffa I, Magnone M, Sociali G, Quercioli A, Pelli G, Lenglet S, Galan K, Burger F, Vázquez Calvo S, Bertolotto M, Bruzzzone S, Ballestrero A, Patrone F, Dallegri F, Santos RAS, Stergiopoulos N, Mach F, Vuilleumier N, Montecucco F. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. ***Thromb Haemost.*** In press 2013.
127. Silva AR, Aguilar EC, Alvarez-Leite JI, da Silva RF, Arantes RM, Bader M, Alenina N, Pelli G, Lenglet S, Galan K, Montecucco F, Mach F, Santos SH, Santos RA. Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE knockout mice. ***Am J Physiol Regul Integr Comp Physiol.*** in press 2013.
126. Fraga-Silva RA, Costa-Fraga FP, Montecucco F, Faye Y, Savergnini SQ, Lenglet S, Mach F, Steffens S, Stergiopoulos N, Santos RA, da Silva RF. Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. ***Clin Dev Immunol.*** In press 2013.
125. Braunersreuther V, Montecucco F, Pelli G, Galan K, Proudfoot AE, Belin A, Vuilleumier N, Burger F, Lenglet S, Caffa I, Soncini D, Nencioni A, Vallée JP, Mach F. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. ***Thromb Haemost.*** In press 2013.
124. Fraga-Silvas RA, Costa-Silva FP, Savergnini SQ, De Sousa FB, Montecucco F, Da Silva DG, Sinisterra RD, Mach F, Stergiopoulos N, da Silva RF, Santos RAS. An oral formulation of Angiotensin-(1-7) protects against hypercholesterolemic-induced corpus cavernosum damages. ***J Sex Med.*** In press 2013.
123. Puddu A, Sanguineti R, Durante A, Nencioni A, Mach F, Montecucco F, Viviani GL. Glucagon Like Peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum. ***Mediators Inflamm.*** 2013;317120, 2013.
122. Quercioli A, Montecucco F, Pataky Z, Thomas A, Ambrosio G, Staub C, Di Marzo V, Ratib O, Mach F, Golay A, Schindler TH. Improvement of Coronary Circulatory Function in Morbidly Obese Individuals after Gastric Bypass induced Weight Loss -Relation to Alterations in Endocannabinoids and Adipocytokines-. ***Eur Heart J.*** 34:2063-73, 2013.
121. Vuilleumier N, Montecucco F, Spinella G, Pagano S, Bertolotto M, Pane B, Pende A, Galan K, Roux-Lombard P, Combescure C, Dallegri F, Mach F, Palombo D. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. ***Thromb Haemost.*** 109:706-15, 2013.
120. Copin JC, da Silva RF, Fraga-Silva RA, Capettini L, Quintao S, Lenglet S, Pelli G, Galan K, Burger F, Braunersreuther V, Schaller K, Deruaz M, Proudfoot AE, Dallegri F, Stergiopoulos N, Santos RAS, Gasche Y, Mach F, Montecucco F. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. ***J Cereb Blood Flow Metab.*** 33:490-8, 2013.
119. Wick PA, Mombelli A, Pagano S, Moren X, Giannopoulou C, Mach F, Roux-Lombard P, Vuilleumier N. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis. ***J Periodontal Res.*** 48:350-6, 2013.
118. Montecucco F, Bauer I, Braunersreuther V, Bruzzzone S, Akhmedov A, Lüscher TF, Speer T, Poggi A, Mannino E, Pelli G, Galan K, Bertolotto M, Lenglet S, Garuti A, Montessuit C, Lerch R, Pellieux C, Vuilleumier N, Dallegri F, Mage J, Sebastian C, Mostoslavsky R, Gayet-Ageron A, Patrone F, Mach F, Nencioni A. Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction. ***Antioxid Redox Signal.*** 18:630-41, 2013.

117. Maggio AB, Wacker J, Fabrizio Montecucco F, Galan K, Pelli G, Mach F, Beghetti M, Farpour-Lambert NJ. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. *J Pediatr*. 161:1022-1027, 2012.
116. Quercioli A, Montecucco F, Galan K, Ratib O, Roux-Lombard P, Pagano S, Mach F, Schindler TH, Vuilleumier N. Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals. *Mediators Inflamm*. 2012:243158, 2012.
115. Montecucco F, Braunersreuther V, Lenglet S, Delattre BMA, Pelli G, Buatois V, Guilhot F, Galan K, Vuilleumier N, Ferlin W, Fischer N, Vallée JP, Kosco-Vilbois M, Mach F. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. *Eur Heart J*. 33:1964-74, 2012.
114. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 367:2089-99, 2012.
113. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. *N Engl J Med*. 366:20-33, 2012.
112. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. *JAMA*. 308:777-87, 2012.
111. Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavriil A, Lyytikäinen LP, Lehtimäki T, Sigala F, Folkersen L, Gorgoulis V, Lenglet S, Montecucco F, Mach F, Hedin U, Hansson GK, Monaco C, Andreaskos E. Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. *Circulation*. 126:952-62, 2012.
110. Quercioli A, Pataky Z, Montecucco F, Carballo S, Thomas A, Staub C, Di Marzo V, Vincenti G, Ambrosio G, Ratib O, Golay A, Mach F, Harsch E, Schindler TH. Coronary Vasomotor Control in Obesity and Morbid Obesity: Contrasting Flow Responses with Endocannabinoids, Leptin, and Inflammation. *JACC Cardiovasc Imaging*. 5:805-15, 2012.
109. Vincenti GM, Ambrosio G, Hyacinthe JN, Quercioli A, Seimbille Y, Mach F, Ratib O, Vallée JP, Schindler TH. Matching between regional coronary vasodilator capacity and corresponding circumferential strain in individuals with normal and increasing body weight. *J Nucl Cardiol*. 19:693-703, 2012.
108. Reny JL, Berdagué P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, Fontana P. Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients: Results of the ADRIE Study. *Circulation*. 125:3201-3210, 2012.
107. Pfenniger A, Wong C, Sutter E, Cuhlmann S, Dunoyer-Geindre S, Mach F, Horrevoets AJ, Evans PC, Krams R, Kwak BR. Shear stress modulates the expression of the atheroprotective protein Cx37 in endothelial cells. *J Mol Cell Cardiol*. 53:299-309, 2012.
106. Kossovsky M, Keller P, Mach F, Gaspoz J. Fondaparinux versus enoxaparin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis. *Swiss Med Wkly*. 2012 Mar 19;142:w13536.
105. Pfenniger A, van der Laan SW, Foglia B, Dunoyer-Geindre S, Haefliger JA, Winnik S, Mach F, Pasterkamp G, James RW, Kwak BR. Lack of association between connexin40 polymorphisms and coronary artery disease. *Atherosclerosis*. 222:148-53, 2012.
104. Kalesan B, Pilgrim T, Heinemann K, Räber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F, Lüscher TF, Meier B, Windecker S, Jüni P. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. *Eur Heart J*. 33:977-87, 2012.

103. Keller PF, Pagano S, Roux-Lombard P, Sigaud P, Rutschmann OT, Mach F, Hochstrasser D, Vuilleumier N. Auto-antibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. *J Intern Med.* 271:451-62, 2012.
102. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Bertolotto M, Pelli G, Galan K, Pilet L, Kuzmanovic K, Burger F, Pane B, Spinella G, Braunersreuther V, Gayet-Ageron A, Pende A, Viviani GL, Palombo D, Dallegri F, Roux-Lombard P, Santos RAS, Stergiopoulos N, Steffens S, Mach F. The activation of the cannabinoid receptor type 2 (CB<sub>2</sub>) reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. *Eur Heart J.* 33:977-87, 2012.
101. Delattre B, Van De Ville D, Braunersreuther V, Pellioux C, Hyacinthe J, Lerch R, Mach F, Vallee J. High Time-Resolved Cardiac Functional Imaging Using Temporal Regularization for Small Animal on a Clinical 3T Scanner. *IEEE Trans Biomed Eng.* 59:929-35, 2012.
100. Delattre BM, Braunersreuther V, Gardier S, Hyacinthe JN, Crowe LA, Mach F, Vallée JP. Manganese kinetics demonstrated double contrast in acute but not in chronic infarction in a mouse model of myocardial occlusion reperfusion. *NMR Biomed.* 25:489-97, 2012.
99. Rossier MF, Pagano S, Python M, Maturana AD, James RW, Mach F, Roux-Lombard P, Vuilleumier N. Antiapolipoprotein A-1 IgG Chronotropic Effects Require Nongenomic Action of Aldosterone on L-Type Calcium Channels. *Endocrinology.* 153:1269-78, 2012.
98. Maggio AB, Farpour-Lambert NJ, Montecucco F, Pelli G, Marchand LM, Schwitzgebel V, Mach E, Aggoun Y, Beghetti M. Elevated E-selectin and diastolic blood pressure in diabetic children. *Eur J Clin Invest.* 42:303-309, 2012.
97. Quercioli A, Mach F, Bertolotto M, Lenglet S, Vuilleumier N, Galan K, Pagano S, Braunersreuther V, Pelli G, Pistoia V, Bianchi G, Cittadini G, Viviani GL, PendeA, Roux-Lombard P, Thomas A, Staub C, Ratib O, Dallegri F, Schindler TH, Montecucco F. Receptor activator of NF- $\kappa$ B ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. *Thromb Haemost.* 107:124-39, 2012
96. Arnaud C, Beguin PC, Lantuejoul S, Pepin JL, Guillermet C, Pelli G, Burger F, Buatois V, Ribout C, Baguet JP, Mach F, Levy P, Dematteis M. The Inflammatory Pre-Atherosclerotic Remodeling Induced by Intermittent Hypoxia is Attenuated by RANTES/CCL5 Inhibition. *Am J Respir Crit Care Med.* 184:724-31, 2011.
95. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med.* 365:699-708, 2011.
94. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. *N Engl J Med.* 364:928-938, 2011.
93. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. *Eur Heart J.* 32:1369-78, 2011.
92. Frossard JL, Lenglet S, Montecucco F, Steffens S, Galan; K, Pelli G, Spahr L, Mach F, Hadengue A. Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. *J Clin Pathol.* 64:387-93, 2011.
91. Montecucco F, Bertolotto M, Vuilleumier N, Franciosi U, Puddu A, Minetti S, Delrio A, Quercioli A, Bergamini E, Ottonello L, Pende A, Lenglet S, Pelli G, Mach F, Dallegri F, Viviani G. *Am J Physiol Endocrinol Metab.* 300:E681-E690, 2011.
90. Brochériou I, Maouche S, Durand H, Braunersreuther V, Le Naour G, Gratchev A, Koskas F, Mach F, Kzhyshkowska J, Ninio E. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. *Atherosclerosis.* 214:316-324, 2011.
89. Fokstuen S, Munoz A, Melacini P, Iliceto S, Perrot A, Ozcelik C, Jeanrenaud X, Rieubland C, Farr M, Faber L, Sigwart U, Mach F, Lerch R, Antonarakis SE, Blouin JL. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. *J Med Genet.* 48:572-6, 2011.

88. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L. Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results from CORONA. **Circ Heart Fail.** 4:145-152, 2011.
87. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, Pelli G, Kovari E, Pane B, Spinella G, Pende A, Palombo D, Dallegri F, Mach F, Roux-Lombard P. Anti-ApoA-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. **Eur Heart J.** 32:412-421, 2011.
86. Fontana P, Berdagué P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, De Moerloose P, Reny JL. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. **J Thromb Haemost.** 8:2614-2623, 2010.
85. Meyer P, Kayser B, Kossovsky MP, Sigaud P, Carballo D, Keller PF, Martin XE, Farpour-Lambert N, Pichard C, Mach F. Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. **Eur J Cardiovasc Prev Rehabil.** 17:569-575, 2010.
84. Valenta I, Quercioli A, Vincenti G, Nkoulou R, Dewarrat S, Rager O, Zaidi H, Seimbille Y, Mach E, Ratib O, Schindler TH. Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT. **J Nucl Cardiol.** 17:1023-1033, 2010.
83. Vuilleumier N, Pagano S, Bas S, Montecucco F, Guerne PA, Finckh A, Lovis C, Mach F, Hochstrasser D, Poux-Lombard P, Gabay C. Anti-Apolipoprotein A-1 IgG predict major cardiovascular events in patients with rheumatoid arthritis. **Arthritis Rheum.** 2010;62:2640-2650.
82. Vincenti G, Quercioli A, Zaïdi H, Nkoulou R, Dewarrat S, Rager O, Ambrosio G, Seimbille Y, Mach F, Ratib O, Schindler TH. Combined evaluation of myocardial perfusion and coronary morphology in the identification of subclinical CAD. Radiation exposure of 13N-ammonia PET/CT. **Nuklearmedizin.** 49(5), 2010.
81. Thomas A, Déglon J, Lenglet S, Mach E, Mangin P, Wolfender JL, Steffens S, Staub C. High-Throughput Phospholipidic Fingerprinting by Online Desorption of Dried Spots and Quadrupole-Linear Ion Trap Mass Spectrometry: Evaluation of Atherosclerosis Biomarkers in Mouse Plasma. **Anal Chem.** 82:6687-6694, 2010.
80. Montecucco F, Lenglet S, Braunersreuther V, Pelli G, Pellieux C, Montessuit C, Lerch R, Deruaz M, Proudfoot AE, Mach F. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. **Arterioscler Thromb Vasc Biol.** 30:1371-7, 2010.
79. Montecucco F, Lenglet S, Gayet-Ageron A, Bertolotto M, Pelli G; Palombo D, Pane B, Spinella G, Steffens S, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach F. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. **Stroke.** 41:1394-404, 2010.
78. Delattre BM, Braunersreuther V, Hyacinthe JN, Crowe LA, Mach F, Vallée JP. Myocardial infarction quantification with Manganese-Enhanced MRI (MEMRI) in mice using a 3T clinical scanner. **NMR Biomed.** 23:503-13, 2010.
77. Groscurin O, Plojoux J, Keller PF, Niquille M, N'koulou R, Mach F, Sarasin FP, Rutschmann OT. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in ST-elevation myocardial infarction. **Swiss Med Wkly.** 140:228-32, 2010.
76. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, Mach F, Petri-Fink A, Hofmann H, Morel DR, Vallée JP, Montet X. In vivo labeling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. **Eur Heart J.** 31:1410-20, 2010.
75. Carballo D, Auer R, Carballo S, Windecker S, Matter C, Luscher T, Vogt P, Perneger T, Mach E, Rodondi N, Keller PF; SPUM-ACS. [A Swiss multicentric project to improve the prevention of cardiovascular event recurrence after acute coronary syndromes] **Rev Med Suisse.** 6:518, 520-2, 524, 2010.
74. Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, James R, Reber G, Mach F, Roux-Lombard P. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. **Eur Heart J.** 31:815-823, 2010.

73. van der Harst P, Slart RH, Tio RA, Dunselman PH, Willemsen AT, van den Heuvel AF, Voors AA, van Veldhuisen DJ; CORONA Study Group. Effects of Rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). **Am J Cardiol.** 105: 517-521, 2010.
72. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, Weber C, Proudfoot A, Mach F, Arnaud C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. **J Mol Cell Cardiol.** 48: 789-798, 2010.
71. Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, Jánosi A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ; CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA Trial. **Eur J Heart Fail.** 12: 66-74, 2010.
70. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and Design of the dual-OUTCOMES trial: efficacy and safety of docetaxel in patients with recent acute coronary syndromes. **Am Heart J.** 158: 896-901.e3, 2009.
69. Bonvini RF, Rastan A, Sixt S, Noory E, Beschoner U, Leppanen O, Mach F, Schwarzwälder U, Bürgelin K, Zeller T. Percutaneous retrieval of intravascular and intracardiac foreign bodies with a dedicated three-dimensional snare: A 3-year single center experience. **Catheter Cardiovasc Interv.** 74: 939-45, 2009.
68. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; for the CORONA Study Group. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis. **Circulation.** 120: 2188-96, 2009.
67. Montecucco F, Bertolotto M, Ottonello L, Pende A, Dapino P, Quercioli A, Mach F, Dallegri F. Chlorhexidine prevents hypochlorous acid-induced inactivation of alpha-1-antitrypsin (alpha-1-AT). **Clin Exp Pharmacol Physiol.** 36: e72-e77, 2009.
66. Montecucco F, Bertolotto M, Ottonello L, Quercioli A, Mach F, Dallegri F. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. **J Biomed Biotechnol.** 2009:478785, 2009.
65. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provisional eptifibatid in acute coronary syndromes. **N Engl J Med.** 360: 2176-90, 2009.
64. Vincenti G, Nkoulou R, Steiner C, Imperiano H, Ambrosio G, Mach F, Ratib O, Vallee JP, Schindler TH. Noninvasive stress testing of myocardial perfusion defects: head-to-head comparison of thallium-201 SPECT to MRI perfusion. **J Nucl Cardiol.** 16: 549-61, 2009.
63. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, Steffens S, Di Marzo V. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. **Atherosclerosis.** 205: 433-41, 2009.
62. Pellegrin M, Alonso F, Aubert JF, Bouzourene K, Braunersreuther V, Mach F, Haefliger JA, Hayoz D, Berthelot A, Nussberger J, Laurant P, Mazzolai L. Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. **Hypertension.** 53: 782-9, 2009.
61. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. **J Mol Cell Cardiol.** 46: 612-20, 2009.
60. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F; Ubolyam S; Carr A, Ruxungham K, Hirschel B, Ananworanich J. HIV increases cardiovascular risk markers in a randomized, treatment interruption trial (STACCATO). **AIDS.** 23: 929-39, 2009.
59. Montecucco F, Burger F, Pelli G, Kwabena Poku N, Berlier C, Steffens S, Mach F. Statins inhibit CRP-induced chemokine secretion, ICAM-1 expression and chemotaxis in adherent human monocytes. **Rheumatology.** 48: 233-42, 2009.

58. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. *Am Heart J.* 156: 826-32, 2008.
57. Saudan P, Muller H, Feraille E, Martin PY, Mach F. Renin-angiotensin system blockade and contrast-induced renal toxicity. *J Nephrol.* 21:681-85, 2008.
56. Montecucco F, Steffens S, Burger F, Pelli G, Monaco C, Mach F. C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. *J Leukoc Biol.* 84:1109-19, 2008.
55. Fokstuen S, Lyle R, Munoz A, Gehrig C, Lerch R, Perrot A, Osterziel KJ, Geier C, Beghetti M, Mach F. Sztajzel J, Sigwart U, Antonarakis SE, Blouin JL. A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. *Hum Mutat.* 29:879-85, 2008.
54. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. *Arterioscler Thromb Vasc Biol.* 28:1090-96, 2008.
53. Montecucco F, Burger F, Mach F. Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. *Am J Physiol Heart Circ Physiol.* 294:H1145-1155, 2008.
52. Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolotto M, Mach F. Dallegri F, Ottonello L. Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. *Cell Signal.* 20:557-68, 2008.
51. von Lukowicz T, Hassa PO, Lohmann C, Borén J, Braunersreuther V, Mach F. Odermatt B, Gersbach M, Camici GG, Stähli BE, Tanner FC, Hottiger MO, Lüscher TF, Matter CM. PARP1 is required for adhesion molecule expression in atherogenesis. *Cardiovasc Res.* 78:158-66, 2008.
50. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19\*2 allele on clopidogrel responsiveness. *Thromb Res.* 121:463-68, 2008.
49. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James RW, Mach F. Chevrolet JC, Dayer JM, Frostegard J, Roux-Lombard P. Anti-apolipoprotein A-1 IgG are associated with high oxidized low-density lipoprotein levels in acute coronary syndrome. *Clin Sci (Lond).* 115:25-33, 2008.
48. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarsen A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F. Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med.* 357:2248-61, 2007.
47. Schindler TH, Zhang XL, Vincenti G, Mhiri L, Nkoulou R, Just H, Ratib O, Mach F. Dahlbom M, Schelbert HR. Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction. *J Nucl Cardiol.* 14:688-97, 2007.
46. Packard RR, Schlegel S, Senouf D, Burger F, Sigaud P, Perneger T, Siegrist CA, Mach F. Atorvastatin treatment and vaccination efficacy. *J Clin Pharmacol.* 47:1022-1027, 2007.
45. Dunoyer-Geindre S, Kwak BR, Pelli G, Roth I, Satta N, Fish RJ, Reber G, Mach F. Kruithof EK, de Moerloose P. Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. *Thromb. Haemost.* 97:129-38, 2007.
44. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Weber C, Mach F. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. *Arterioscler Thromb Vasc Biol.* 27:373-379, 2007.

43. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F. Short-term treatment with CD3 antibody reduces the development and progression of atherosclerosis in mice through the induction of FoxP3-expressing regulatory T cells. *Circulation*. 114:1977-84, 2006.
42. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. *Atherosclerosis*. 188:51-58, 2006.
41. Frossard J-L, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. CD40 Ligand-deficient mice in pancreatitis. *World J. Gastroenterol*. 12:1613-1616, 2006.
40. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Not all statins interfere with clopidogrel during antiplatelet therapy. *Eur. J. Clin. Invest*. 35:476-481, 2005.
39. Veillard NR, Steffens S, Pelli G, Kwak BR, Gerard C, Lu B, Charo IF, Mach F. Differential influence of the chemokine receptors CCR2 and CXCR3 in the development of atherosclerosis in vivo. *Circulation*. 112:870-878, 2005.
38. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. *Cardiovasc. Res*. 66:583-593, 2005.
37. Christen T, Mach F, Didier D, Kalangos A, Verin V, Trindade PT. Late cardiac tamponade after percutaneous closure of a patent foramen ovale. *Eur. J. Echocardiogr*. 6:465-469, 2005.
36. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F. Statins reduce interleukin-6-induced C-Reactive Protein in human hepatocytes. New evidence for direct anti-inflammatory effects of statins. *Arterioscler. Thromb. Vasc. Biol*. 25:1231-1236, 2005.
35. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer H, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. *Nature*. 434:782-786, 2005.
34. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway. Implications for atherosclerotic endothelial dysfunction. *Circulation*. 110:3708-3714, 2004.
33. Veillard N, Steffens S, Burger F, Pelli G, Mach F. Differential expression pattern of pro-and anti-inflammatory mediators during atherogenesis in mice. *Arterioscler. Thromb. Vasc. Biol*. 24:2339-2344, 2004.
32. Pastor CM, Pugin J, Kwak B, Chanson M, Mach F, Hadengue A, Frossard JL. Role of Toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. *Crit. Care Med*. 32:1759-1763, 2004.
31. Veillard N, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AEI, Mach F. Antagonist of RANTES receptors reduces atherosclerotic plaque formation in mice. *Circ. Res*. 94:253-261, 2004.
30. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY. Safety of low-dose spironolactone administration in chronic haemodialysis patients. *Nephrol. Dial. Transplant*. 18:2359-2363, 2003.
29. Dimitrova Y, Dunoyer-Geindre S, Reber G, Mach F, Kruihof EK, de Moerloose P. Effects of statins on adhesion molecule expression in endothelial cells. *J. Thromb. Haemost*. 11:2290-9, 2003.
28. Mulhaupt F, Matter CM, Kwak B, Pelli G, Veillard N, Burger F, Graber P, Lüscher TF, Mach F. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. *Cardiovasc. Res*. 59:755-766, 2003.
27. Kwak B, Veillard N, Pelli G, Mulhaupt F, James R, Chanson M, Mach F. Reduced connexin43 expression inhibits atherosclerotic lesion formation in LDL-receptor deficient mice. *Circulation*. 107:1033-1039, 2003.
26. Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, Weiner HL. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor deficient-mice. *Circulation*. 106:1708-1715, 2002.

25. Bosquet S, Sunthorn H, Zaim Z, Lerch R, Mach F. Right atrial thrombus formation after radiofrequency catheter ablation of a left-side accessory pathway using a transseptal approach. ***Pace Pacing Clin. Electrophysiol.*** 25:1146-48, 2002.
24. Kwak B, Mulhaupt F, Veillard N, Pelli G, Gros G, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. ***Arterioscler. Thromb. Vasc. Biol.*** 22:225-230, 2002.
23. Kwak B, Myit S, Mulhaupt F, Veillard N, Pelli G, Mach F. PPARgamma but not PPARalpha activators reduce IFN-gamma induced MHC class II expression on human endothelial cells and monocyte/macrophages: Role for PPARs as immunosuppressor ? ***Circ. Res.*** 90:356-362, 2002.
22. Mach F, Sukhova GK, Michetti M, Libby P, Michetti P. Helicobacter Pylori infection does not influence atherogenesis in vivo in a murine model. ***Circ. Res.*** 90:E1-E4, 2002.
21. Frossard J-L, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. CD40 ligand-deficient mice are protected against cerulein-induced acute pancreatitis and pancreatitis associated lung injury. ***Gastroenterology.*** 121:184-194, 2001.
20. Lovis C, Mach F, Unger P-F, Bouille M, Chevrolet J-C. Elevation of creatine kinase during acute severe asthma is not of cardiac origin. ***Intensive Care Med.*** 27:528-533, 2001.
19. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. ***Swiss Med. Wkly.*** 131:41-46, 2001.
18. Kwak B, Mulhaupt F, Myit S, Mach F. Statins (HMG-CoA reductase inhibitors) as a novel type of immunosuppressor. ***Nat. Med.*** 6:1399-1402, 2000.
17. Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RH. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. ***J. Immunol.*** 165:3506-3518, 2000.
16. Schönbeck U, Sukhova GK, Mach F, Shimizu K, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. ***Proc. Nat. Acad. Sci. USA.*** 97:7458-7563, 2000.
15. Mach F, Marx N, Sauty A, Sarafi, Ransohoff R, Libby, Plutzky J, Luster AD. PPARgamma activators inhibit IFN-gamma-induced expression of the T cell-specific CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. ***J. Immunol.*** 164:6503-6508, 2000.
14. Abi-Younes S, Mach F, Sauty A, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. ***Circ. Res.*** 86:131-138, 2000.
13. Mach F, Schönbeck U, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. ***Am. J. Pathol.*** 156:7-14, 2000.
12. Mach F, Sauty A, Sukhova GK, Libby P, Luster AD. The interferon-gamma inducible CXC-chemokines IP-10, Mig and I-TAC are expressed by human atheroma-associated cells: Implication for lymphocyte recruitment in atherogenesis. ***J. Clin. Invest.*** 104:1041-1050, 1999.
11. Mach F, Schönbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Libby P. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: Implications for tubule formation. ***Am. J. Pathol.*** 154:229-238, 1999.
10. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Levesque E, Graber P, Basset P, Libby P. Expression of Stromelysin-3 in atherosclerotic lesions: Regulation via CD40/CD40 ligand signaling in vitro and in vivo. ***J. Exp. Med.*** 189:843-853, 1999.
9. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. ***Nature.*** 394:200-203, 1998.
8. Mach F, Schönbeck U, Libby P. Generation of biologically active interleukine-1beta (IL-1beta) by matrix metalloproteinases: A novel caspase-1 independent pathway of IL-1beta processing. ***J. Immunol.*** 161:3340-3346, 1998.
7. Mach F, Lovis C, Gaspoz JM, Unger, PF, Bouillie M, Urban P, Rutishauser W. C-reactive protein as a marker for acute coronary syndromes. ***Eur. Heart. J.*** 18:1897-1902, 1997.
6. Gerhardt W, Collinson PO, Katus HA, Müller-Bardorff M, Lovis C, Mach F, Sylven C, Rasmanis G, Leinberger R, Zerback R. An improved rapid troponin T test with a decreased detection

- limit: A multicentre study of the analytical and clinical performance in suspected myocardial damage. *Scand. J. Clin. Lab. Invest.* 57:549-558, 1997.
5. Mach F, Schönbeck U, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture? *Circ. Res.* 81:448-454, 1997.
  4. Mach F, Schönbeck U, Bonnefoy JY, Loppnow H, Flad HD, Libby P. Ligation of CD40 activates interleukin 1beta-converting enzyme activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. *J. Biol. Chem.* 272:19569-19574, 1997.
  3. Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complications by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. *Circulation* 96:396-399, 1997.
  2. Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: Implication for CD40-CD40 ligand signaling in atherosclerosis. *Proc. Natl. Acad. Sci. USA.* 94:1931-1936, 1997.
  1. Mach F, Lovis C, Chevolet JC, Urban P, Unger PF, Bouillie M, Gaspoz JM. Rapid bedside whole blood cardiospecific troponin T immunoassay for the diagnosis of acute myocardial infarction. *Am. J. Cardiol.* 75:245-248, 1995.

## **Reviews**

112. Malekzadeh S, Fraga-Silva RA, Trachet B, Montecucco F, Mach F, Stergiopoulos N. Role of the Renin-Angiotensin System on Abdominal Aortic Aneurysms. *Eur J Clin Invest.* In press 2013.
111. Carbone F, Montecucco F, Mach F. Update on evidence for treatment with ranolazine in stable angina. *Swiss Med Wkly.* in press 2013.
110. Carbone F, Montecucco F, Mach F, Pontremoli R, Viazzi F. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. *Thromb Haemost.* in press 2013.
109. Rosa GM, Bauckneht M, Masoero G, Mach F, Quercioli A, Seitun S, Balbi M, Brunelli C, Parodi A, Nencioni A, Vuilleumier N, Montecucco F. The vulnerable coronary plaque: update on imaging technologies. *Thromb Haemost.* in press 2013.
108. Lenglet S, Montecucco F, Mach F. Role of matrix metalloproteinases in animal models of ischemic stroke. *Curr Vasc Pharmacol.* In press 2013.
107. Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F. Pathophysiological role of neutrophils in acute myocardial infarction. *Thromb Haemost.* in press 2013.
106. Fraga-Silva RA, Montecucco F, Mach F, Santos RAS, Stergiopoulos N. Pathophysiological role of the Renin-Angiotensin System on erectile dysfunction. *Eur J Clin Invest.* 43:978-85, 2013.
105. Asrih M, Mach F, Quercioli A, Dallegri F, Montecucco F. Update on the pathophysiological activities of the cardiac molecule Cardiotrophin-1 in obesity. *Mediators Inflamm.* 2013:370715, 2013.
104. Puddu A, Sanguineti R, Mach F, Dallegri F, Viviani G, Montecucco F. Update on the protective molecular pathways improving pancreatic beta-cell dysfunction *Mediators Inflamm.* 2013:750540, 2013.
103. Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. *Thromb Haemost.* 33:490-8, 2013.
102. Puddu A, Mach F, Nencioni A, Viviani G, Montecucco F. An emerging role of Glucagon-like peptide-1 (GLP-1) in preventing Advanced Glycation End-Product (AGE)-mediated damages in diabetes. *Mediators Inflamm.* 2013:591056, 2013.
101. Asrih M, Mach F, Nencioni A, Dallegri F, Quercioli A, Montecucco F. Role of mitogen activated protein (MAP) kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. *Mediators Inflamm.* 2013:367245, 2013.

100. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase (MMP)-8 in atherosclerosis. *Mediators Inflamm.* 2013:659282, 2013.
99. Michel-Monigadon D, Steffens S, Molica F, Mach F, Montecucco F. Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology. *Expert Rev Cardiovasc Ther.* 2012;10:1481-1486, 2012.
98. Fraga-Silva RA; Da Silva DG, Montecucco F, Mach F, Stergiopoulos N, da Silva RF, Santos RAS. The Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. *Thromb Haemost.* 108:1089-96, 2012.
97. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol.* 18:727-35, 2012.
96. Gallino A, Stuber M, Crea F, Falk E, Corti R, Lekakis J, Schwitter J, Camici P, Gaemperli O, Di Valentino M, Prior J, Garcia-Garcia HM, Vlachopoulos C, Cosentino F, Windecker S, Pedrazzini G, Conti R, Mach F, De Caterina R, Libby P. "In vivo" imaging of atherosclerosis. *Atherosclerosis.* 224:25-36, 2012.
95. Mirabelli-Badenier M, Braunersreuther V, Lenglet S, Galan K, Veneselli E, Viviani GL, Mach F, Montecucco F. Pathophysiological role of inflammatory molecules in paediatric ischemic brain injury. *Eur J Clin Invest.* 42:784-94, 2012.
94. Braunersreuther V, Mach F, Montecucco F. Reactive oxygen-induced cardiac intracellular pathways during ischemia and reperfusion *Current Signal Transduction Therapy.* 7:89-95, 2012.
93. Capettini LS, Savergnini SQ, da Silva RF, Stergiopoulos N, Santos RA, Mach F, Montecucco F. Update on the role of cannabinoid receptors after ischemic stroke. *Mediators Inflamm.* 2012:824093, 2012.
92. Lenglet S, Thomas A, Chaurand P, Galan K, Mach F, Montecucco F. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. *Thromb Haemost.* 107:409-16, 2012.
91. Montecucco F, Braunersreuther V, Viviani GL, Lenglet S, Mach F. Update on the pathophysiological role of intracellular signalling pathways in atherosclerotic plaques and ischemic myocardium. *Current Signal Transduction Therapy.* 7:104-10, 2012.
90. Capettini LSA, Montecucco F, Mach F, Stergiopoulos N, Santos RA, da Silva RF. Role of Renin-Angiotensin system in Inflammation, Immunity and Aging. *Curr Pharm Des.* 18:963-70, 2012.
89. Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. *Curr Pharm Biotechnol.* 13:68-76, 2012.
88. Lenglet S, Mach F, Montecucco F. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. *Expert Rev Cardiovasc Ther.* 9:1519-25, 2011.
87. Yarol N, Tozzi P, von Segesser L, Kalangos A, Vogt P, Yerly P, Mach F, Pascual M, Meyer P, Hullin R. [Selection and preoperative follow-up of heart transplantation candidates in the French part of Switzerland]. *Rev Med Suisse.* 7:1212-1216, 2011.
86. Thomas A, Lenglet S, Chaurand P, Deglon J, Mangin P, Mach F, Steffens S, Wolfender JL, Staub C. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. *Thromb Haemost.* 106:20-33, 2011.
85. Mirabelli-Badenier M, Braunersreuther V, Viviani GL, Dallegri F, Quercioli A, Veneselli E, Mach F, Montecucco F. CC and CXC chemokines are pivotal mediators of cerebral injury in ischemic stroke, *Thromb Haemost.* 105:409-420, 2011.
84. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. *J Nephrol.* 24:23-34, 2011.
83. Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F. New evidence for nicotinic acid treatment to reduce atherosclerosis. *Expert Rev Endocrinol Metab.* 8:1457-1467, 2010.
82. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). *Sleep Breath.* 14:261-9, 2010.
81. Quercioli A, Montecucco F, Bertolotto M, Ottonello L, Pende A, Mach F, Dallegri F. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. *Eur J Clin Invest.* 40:645-54, 2010.

80. Kummer O, Roffi M, Marti G, Mach F. Clopidogrel and its salts: any clinical implication? *Rev Med Suisse*. 6:1127-8, 1130-2, 2010.
79. Quercioli A, Mach F, Montecucco F. Novel treatment strategy with direct renin inhibition against heart failure. *Panminerva Med*. 52: 41-51, 2010.
78. Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. *Expert Opin Drug Saf*. 8: 715-25, 2009.
77. Quercioli A, Montecucco F, Mach F. Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD). *Cardiovasc Hematol Disord Drug Targets*. 9: 261-70, 2009.
76. Meyer P, Kayser B, Mach F. Stair use for cardiovascular disease prevention. *Eur J Cardiovasc Prev Rehabil*. 16 Suppl 1: S17-8, 2009.
75. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischemia and reperfusion injury. *Thromb Haemost*, 102: 240-7, 2009.
74. Yerly P, Mach F, Kalangos A, Rotman S, von Segesser L, Vogt P, Hullin R, Pascual M. Monitoring and adjustment of immunosuppression after the heart transplantation. *Rev Med Suisse*. 5: 1214-6, 1218-20, 2009.
73. Luya Schmidt A, Mach F. Takotsubo syndrome: myth or reality? *Rev Med Suisse*. 5: 1184, 1186-8, 1190-2 passim, 2009.
72. Roffi M, Pereira V, San MD, Bonvini RF, Keller PF, Mach F, Lovblad KO. Carotid stenting: an alternative to surgery? *Rev Med Suisse*. 2009 5: 1177-80, 1182-3, 2009.
71. Vogt P, Mach F. Cardiology-trends. *Rev Med Suisse*. 5: 1163-4, 2009.
70. Mach F. Ivabradine, an I(f) current inhibitor--new treatment options in coronary heart disease. *Rev Med Suisse*. 5: 1168-70, 1172-3, 2009.
69. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. *Semin Immunopathol*. 31: 127-142, 2009.
68. Montecucco F, Mach F. ACE-inhibitors and ARB in cardiovascular disease. *Best Pract Res Clin Endocrinol Metab*. 23: 389-400, 2009.
67. Montecucco F, Mach F. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. *Diabetes, Obesity and Metabolism*. 11: 445-454, 2009.
66. Bonvini RF, Reny JL, Mach F, Zeller T, Fontana P. Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistanc. *Curr Vasc Pharmacol*. 7: 198-208, 2009.
65. Lévy P, Pépin JL, Arnaud C, Baguet JP, Dematteis M, Mach F. Obstructive sleep apnea and atherosclerosis. *Prog Cardiovasc Dis*. 51: 400-10, 2009.
64. Montecucco F, Mach F. Therapeutic approaches for reducing C-reactive protein (CRP) levels and the associated cardiovascular risk. *Current Chemical Biology*. 3: 60-64, 2009.
63. Montecucco F, Pende A Mach F. The renin-angiotenin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical trials. *Mediators Inflamm*. 2009:752406, 2009.
61. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. *Rheumatology*. 48:11-22, 2009.
61. Mach F, Montecucco F, Steffens S. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. *Pharmacol Rep*. 61:13-21, 2009.
60. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? *Endocrine, Metabolis & Immune Disorders – Drug Targets*. 8: 301-307, 2008.
59. Montecucco F, Mach F. Traitement du diabète de type 2: Blocage du système endocannabinoïde avec le rimonabant. *Cardiovasc*. 7:18-20, 2008.
58. Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in arterial intima as a cardiovascular risk factor. *Clin. Interv. Aging*. 3:341-349, 2008.
57. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. *Mediators Inflamm*. 767623, 2008.

56. Mach F, Vogt P. The importance of patient education in cardiology. *Rev. Med. Suisse.* 4:1299-300, 2008.
55. Sekoranjia L, Bianchi-Demicheli F, Gaspoz JM, Mach F. Heart failure and sexual dysfunction. *Rev. Med. Suisse.* 4:763-67, 2008.
54. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. *J. Neuroendocrinol.* 20 Suppl 1:53-57, 2008.
53. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. *Br. J. Pharmacol.* 153:290-98, 2008.
52. Montecucco F, Steffens S, Mach F. Inflammation as coronary risk factor. *ARS MEDICI.* 23:1145-1152, 2007.
51. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? *Clin. Dev. Immunol.* 75805, 2007.
50. Mach F. The endocannabinoid system as therapeutic target to reduce atherosclerosis. *Drug News Perspect.* 2007.
49. Clark R, Mach F. L'Ezitimibe sous la loupe. *Drug in Context.* 2007.
48. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. *Thromb Haemost.* 97:714-21, 2007.
47. Purcell H, Mach F. Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine. *Rev. Med. Suisse.* 3:1375-8, 2007.
46. Steffens S, Mach F. Cannabinoid receptors in atherosclerosis. *Curr. Opin. Lipid.* 17:519-26, 2006.
45. Braunersreuther V, Mach F. Leukocytes recruitment in atherosclerosis: Potential targets for therapeutical approaches ? *Cell. Mol. Life. Sci.* 63:2079-88, 2006.
44. Steffens S, Mach F. Immunomodulatory effects of statins: Potential benefits for renal patients. *Nat. Clin. Pract. Neph.* 2:378-87, 2006.
43. Mach F. New anti-inflammatory agents to reduce atherosclerosis. *Arch. Physiol. Biochem.* 112:130-7, 2006.
42. Arnaud C, Mach F. Potential anti-inflammatory and immunomodulatory effects of statins in rheumatologic therapy. *Arthritis Rheum.* 54:579-586, 2006.
41. Mach F. New anti-inflammatory agents to reduce atherosclerosis. *NAF Review* 3:2, 2006.
40. Sekoranjia L, Bianchi-Demicheli F, Gaspoz JM, Mach F. Erectile dysfunction: a potential useful marker for cardiovascular disease. *Rev. Med. Suisse* 2:774-778, 2006.
39. Steffens S, Mach F. Vers un usage thérapeutique de ligands sélectifs du récepteur cannabinoïde 2 dans l'athérosclérose. *Med. Sci.* 22:7-9, 2005.
38. Steffens S, Mach F. Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. *Future Cardiol.* 2:49-53, 2005.
37. Mach F. Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. *Handb. Exp. Pharmacol.* 170:697-722, 2005.
36. Mach F. Traitement antithrombotique et thrombolytique: Commentaire des experts suisses concernant les EBM-guideles internationales. *Swiss Med. Wkly.* 28:28S-33S, 2005.
35. Arnaud C, Braunersreuther, Mach F. Towards immunodulatory and anti-inflammatory properties of Statins. *Trends Cardiovasc. Med.* 15:202-206, 2005.
34. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis. *Arch. Mal. Coeur Vaiss.* 98:661-666, 2005.
33. Arnaud C, Veillard N, Mach F. Cholesterol-independent effects of statins. *Curr. Drug. Targets.* 5:127-134, 2005.
32. Fokstuen S, Blouin JL, Lyle R, Lerch R, Beghetti M, Mach F, Sztajzel J, Antonarakis SE, Sigwart U. The contribution of molecular genetics to clinical cardiology: the example of hypertrophic cardiomyopathy. *Rev. Med. Suisse.* 1:1448-1450, 2005.

31. Braunersreuther V, Mach F. Mécanisme d'action des statines: A la recherche des effets pléiotropiques ? **Cardiovasc.** 3:24-27, 2005.
30. Steffens S, Mach F. Anti-inflammatory properties of statins. **Semin. Vasc. Med.** 4:417-422, 2004.
29. Steffens S, Mach F. Inflammation and atherosclerosis. **Herz.** 29:741-748, 2004.
28. Mach F. Statins as immunomodulatory agents. **Circulation.** 109:15-17, 2004.
27. Corti R, Spieker LE, Eberli FR, Mach F, Buser P, Rickenbacher P, Meier B, Lüscher TF. Thienopyridine platelet antagonists in acute coronary syndrome after PCI – Practical recommendations. **Kardiovask. Medizin.** 7:159-173, 2004.
26. Mach F. Guidelines: Entzündung und Infektion als kardiovaskuläre Risikofaktoren. **Cardiovasc.** 85:2460, 2004.
25. Wong CW, Burger F, Pelli G, Mach F, Kwak BR. Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice. **Cell. Commun. Adhes.** 10:395-400, 2003.
24. Kwak B, Mulhaupt F, Mach F. Atherosclerosis. Anti-inflammatory and immunomodulators effects of statins. **Autoimmunity.** 2:332-338, 2003.
23. Mach F. Statins as a novel immunomodulators. From cell to potential clinical benefit. **Thromb. Haemostasis.** 90:607-610, 2003.
22. Fokstuen S, Mach F, Antonarakis SE, Sztajzel J. Le conseil génétique en cardiologie: l'exemple de la dysplasie arythmogène du ventricule droit. **Med. Hyg.** 61:414-418, 2003.
21. Veillard N, Mach F. Statins: The new Aspirin ? **Cell. Mol. Life. Sci.** 59:1771-1786, 2002.
20. Mach F. Statins as immunomodulators. **Transpl. Immunology.** 9:197-200, 2002.
19. Kwak B, Mulhaupt F, Mach F. The role of PPAR-gamma ligands as regulators of the immune response. **Drug News Perspect.** 15:325-332, 2002.
18. Spieker LE, Eberli FR, Mach F, Beer J, Urban P, Noll G, Buser P, Rickenbacher P, Pfisterer M, Meier B, Lüscher TF. Thienopyridine platelet antagonists in acute coronary syndrome – Practical recommendations based on the CURE study. **Kardiovask. Med.** 5:61-71, 2002.
17. Mach F. Immunosuppressive effects of statins. **Atherosclerosis.** 3:17-20, 2002.
16. Mach F. Echos de XXIVe congrès de la Société européenne de cardiologie. **Med. Hyg.** 61:2133-2135, 2002.
15. Mach F. Effets thérapeutiques et pléiotropiques des statines dans la prévention primaire et secondaire des maladies cardiovasculaires. **Med. Hyg.** 60:967-970, 2002.
14. Mach F. L'athérosclérose est une maladie inflammatoire. **Kardiovask. Med.** 4:160-168, 2001.
13. Mach F. Role of chemokines in atherosclerosis. **Curr. Atheroscler. Rep.** 3:243-251, 2001.
12. Gerszten R, Mach F, Sauty A, Luster AD. Chemokines, leukocytes and atherosclerosis. **J. Lab. Clin. Med.** 136:87-92, 2000.
11. Schönbeck U, Mach F, Libby P. Molecules in focus CD154 (CD40 ligand). **Int. J. Biochem. Cell. Biol.** 32:687-693, 2000.
10. Sztajzel J, Mach F, Righetti A. Role of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries. **Postgrad. Med. J.** 76:16-21, 2000.
9. Mach F. L'athérosclérose: Une maladie inflammatoire. **Med. Hyg.** 58:617-623, 2000.
8. Mach F. Clinical importance of C-reactive protein in acute coronary syndromes. **Cardiol. Rev.** 16:46-49, 1999.
7. Libby P, Mach F, Schonbeck U, Bourcier T, Aikawa M. Regulation of the thrombotic potential of atheroma. **Thromb. Haemost.** 82:736-741, 1999.
6. Mach F, Schönbeck U, Libby P. CD40 signaling in vascular cells: A key mediator in atherosclerosis. **Atherosclerosis.** 137:89-95, 1998.

5. Libby P, Schönbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rupture and stabilization. **Am. J. Med.** 104:14-18, 1998.
4. Libby P, Geng YJ, Aikawa M, Schönbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. **Curr. Opin. Lipid.** 7:330-335, 1996.
3. Lovis C, Mach F, Donati YR, Bonventre JV, Polla BS. Heat shock proteins and the kidney. **Ren. Fail.** 16:179-192, 1994.
2. Lovis C, Mach F. Troponines cardiospécifiques: Nouveaux marqueurs enzymatiques de la lésion myocardique. **Med. Hyg.** 43:1553-1555, 1994.
1. Mach F, Lovis C, Polla BS, Pécoud A. Les antihistaminiques: Des médicaments dangereux ? **Rev. Med. Suisse Romande.** 113:187-190, 1993.

## **Editorials**

22. Gencer B, Noble S, Bonvini RF, Mach F, Roffi M. [Role of percutaneous coronary intervention in diabetic patients]. **Rev Med Suisse.** 9:1137-8, 2013.
21. Mach F, Vogt P. [High quality Cardiology: a "leitmotiv" ]. **Rev Med Suisse.** 9:1131, 2013.
20. Blanche C, Rutz T, Vogt P, Mach F, Beghetti M, Bouchardy J. [Adults with congenital heart diseases: a growing population, a multidisciplinary approach]. **Rev Med Suisse.** 9:1142-4, 2013.
19. Montecucco F, Mach F, Pende A. Inflammation is a Key Pathophysiological Feature of Metabolic Syndrome. **Mediators Inflamm.** 2013:135984, 2013.
18. Asrih M, Lenglet S, Mach F, Montecucco F. Novel limitations of the clinical use of alpha-fetoprotein in the prognosis of small hepatocellular carcinoma. **World J Gastroenterol.** 19:328-30, 2013.
17. Montecucco F, Vuilleumier N, Pende A, Schindler TH, da Silva RF, Mach F. Novel inflammatory cardiovascular biomarkers in the assessment of cardiovascular risk. **Mediators Inflamm.** 2012:515692, 2012.
16. Lenglet S, Mach F, Montecucco F. Matrix metalloproteinase (MMP)-9: a deleterious link between surgical hepatic ischemia-reperfusion and colorectal cancer metastases. **World J Gastroenterol.** 18:7131-3, 2012.
15. Vogt P, Mach F. [Medical education and spatial distribution of cardiologists in Switzerland: can we do better?]. **Rev Med Suisse.** 8:1147-8, 2012.
14. Bieler S, Mach F. [Management of cardiac failure: a guilty one easy to target!]. **Rev Med Suisse.** 8:1154-5, 1157-8. French, 2012.
13. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. **World J Gastroenterol.** 18:727-35, 2012
12. Montecucco F, Mach F. Editorial: Update on inflammatory processes governing atherosclerotic plaque vulnerability and reperfusion injury. **Curr Pharm Biotechnol.** 13:1-3, 2012
11. Montecucco F, Mach F. Should we focus on "venous vulnerability" instead of "plaque vulnerability" in symptomatic atherosclerotic patients? **Thromb Haemost.** 106:995-6, 2011.
10. Mach F, Vogt P. [Trends in cardiology]. **Rev Med Suisse.** 7:1179, 2011.
9. Mach F. [Reducing heart rate to treat angina pectoris]. **Rev Med Suisse.** 7:1276-1280, 2011.
8. Quercioli A, Viviani GL, Dallegri F, Mach F, Montecucco F. RANKL/OPG pathway is a promising target to reduce atherosclerosis plaque calcification. **Crit Pathw Cardiol.** 9:227-230, 2010.
7. Kummer O, Roffi M, Marti G, Mach F. [Clopidogrel and its salts: any clinical implication?] **Rev Med Suisse.** 6:1127-8, 1130-2, 2010.
6. Montecucco F, Mach F. Atherosclerosis is an inflammatory disease. **Semin Immunopathol.** 31: 1-3, 2009.
5. Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. **Circ. Res.** 102: 140, 2008.

4. Mach F. Towards a role for statins in immunomodulation. *Mol. Interv.* 2: 478-80, 2002.
3. Kwak B, Shah D, Mach F. A starting point for structure function relationships in the canine pulmonary veins. *Cardiovasc. Res.* 55: 703-704, 2002.
2. Kwak B, Mach F. Statins inhibit Leukocyte recruitment. New evidence for their anti-inflammatory properties. *Arterioscler. Thromb. Vasc. Biol.* 21: 1256-1258, 2001.
1. Mach F. Towards new therapeutic strategies against neointimal formation in restenosis. *Arterioscler. Thromb. Vasc. Biol.* 20: 1699-1700, 2000.

### Letters

1. Kwak BR, Mach F. Reply to "Statins and the control of CIITA transcription". *Nat. Med.* 11: 366-367, 2005.

### Book chapters

10. Holme MN, Schulz G, Deyhle H, Weitkamp T, Beckmann F, Lobrinus JA, Montecucco F, Mach F., Zumbuehl A, Saxer T, Müller B. Morphology of atherosclerotic human coronary arteries *SPIE volume 8506*, "Developments in X-Ray Tomography VIII". In press 2013.
9. Quercioli A, Mach F., Montecucco F. "Mechanisms underlying endothelial dysfunction in obstructive sleep apnea syndrome (OSAS) patients". *Nova Science Publishers*, Obstructive Sleep Apnea Causes, Treatments and Health Implications 2012, Chapter 6: 117-128.
8. Montecucco F, Noble S, Mach F. Inflammatory biomarkers. Handbook entitled "Inflammation and atherosclerosis" *SpringerWienNewYork*, 2011, Chapter 24:481-497.
7. Montecucco F, Quercioli A, Mach F. Role of neutrophils in acute myocardial infarction. Handbook entitled "Neutrophils: Lifespan, Functions and Role in diseases." *Nova Science Publishers*, Chapter 13:351-360, 2010.
6. Vuille C, Mach F. Prévention Cardiovasculaire: Moyens Thérapeutiques. *Edition Médecine & Hygiène*, 2009.
5. Mach F. Statins in atherosclerosis: Role of immune regulation. Immune Dysfunction and Immunotherapy in Heart Disease. *Ronald R. Watson & Douglas F. Larson Editors. Blackwell*, 2006.
4. Mach F. Statines et médicaments hypolipémiants. *Edition Médecine & Hygiène*, 2006.
3. Mach F. Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular disease. Atherosclerosis: Diet and Dugs. *Arnold von Eckardstein Editor. Springer*, 2005.
2. Mach F. Physiopathologie de l'athérosclérose. Cardiologie *Wilhelm Rutishauser & Juan Sztajzel. Edition Masson*, 2004.
1. Lovis C, Mach F. Des hommes des chiffres. Répertoire des valeurs normales. *Edition Médecine & Hygiène*, 1987.

### Thesis

- Mach F. Le Diagnostic d'Infarctus du myocarde au Lit du Malade par un Nouveau Test Immunologique Rapide pour la Troponine-T. Genève 1994, thèse N: 9584.